Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemetrexed vs Gefitinib in EGFR Wild-Type NSCLC
NCT00891579Phase 2
Key facts
- Status
- Completed
- Start
- Feb 2009
- Primary completion
- Sep 2012
- Countries
- 1
- Sponsor
- Chinese Society of Lung Cancer
- Modality
- Small Molecules
- Drugs
- pemetrexedgefitinib
- Conditions
- non-small cell lung cancer (NSCLC)
01
Overview
Phase 2, randomised, open-label trial of pemetrexed and gefitinib in non-small cell lung cancer (NSCLC), sponsored by Chinese Society of Lung Cancer. Primary endpoint: Progression-Free Survival at 2 years. Started Feb 2009; status: completed.
02
Design
- Study design
- RandomizedOpen-label
03
Who it enrols
Patients with locally advanced or metastatic EGFR wild-type NSCLC who progressed after one platinum-based chemotherapy regimen.
04
Endpoints
Primary
Progression-Free Survival
Beyond the preview
Go deeper on NCT00891579.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00891579.